This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
IRVINE, Calif., Nov. 5, 2013 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a commercial stage medical technology company focused on creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart, announced today that Kimble Jenkins, MRI Interventions' Chief Executive Officer, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York on Thursday, November 14, 2013. The presentation is scheduled to begin at 4:00 p.m. ET. A live webcast of the presentation will be available under the
IR Calendar section of the MRI Interventions website. For those unable to listen to the live webcast, a replay will be available on MRI Interventions' website following the presentation.
About MRI Interventions
Founded in 1998, MRI Interventions (OTCQB:MRIC) is a publicly traded company creating innovative platforms for performing the next generation of minimally-invasive surgical procedures in the brain and heart. Utilizing a hospital's existing MRI suite, the company's FDA-cleared and CE-marked ClearPoint
® system is designed to enable a range of minimally-invasive procedures in the brain. In partnership with Siemens Healthcare, MRI Interventions is developing the ClearTrace
® system to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation. Building on the imaging power of MRI, the company's interventional platforms strive to improve patient care while reducing procedure costs and times. MRI Interventions is also working with Boston Scientific Corporation to incorporate its MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications. For more information, please visit
CONTACT: MRI Interventions, Inc.